These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30516019)

  • 1. Pharmacodynamic Models of Differential Bortezomib Signaling Across Several Cell Lines of Multiple Myeloma.
    Ramakrishnan V; Mager DE
    CPT Pharmacometrics Syst Pharmacol; 2019 Mar; 8(3):146-157. PubMed ID: 30516019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells.
    Ramakrishnan V; Mager DE
    J Pharmacol Exp Ther; 2018 Jun; 365(3):734-751. PubMed ID: 29632237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
    Que W; Chen J; Chuang M; Jiang D
    APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model.
    Kim C; Lee JH; Ko JH; Chinnathambi A; Alharbi SA; Shair OHM; Sethi G; Ahn KS
    Biomolecules; 2019 Jul; 9(7):. PubMed ID: 31284669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.
    Chudasama VL; Ovacik MA; Abernethy DR; Mager DE
    J Pharmacol Exp Ther; 2015 Sep; 354(3):448-58. PubMed ID: 26163548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway.
    Li J; Liu Z; Li Y; Jing Q; Wang H; Liu H; Chen J; Feng J; Shao Q; Fu R
    J Investig Med; 2019 Jan; 67(1):39-47. PubMed ID: 29997148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance.
    Yu W; Chen Y; Xiang R; Xu W; Wang Y; Tong J; Zhang N; Wu Y; Yan H
    Leuk Lymphoma; 2017 Feb; 58(2):428-437. PubMed ID: 27439454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Network-Based Systems Analysis Explains Sequence-Dependent Synergism of Bortezomib and Vorinostat in Multiple Myeloma.
    Nanavati C; Mager DE
    AAPS J; 2021 Aug; 23(5):101. PubMed ID: 34403034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of PLD1 potentiates the antitumor effects of bortezomib in multiple myeloma cells by inhibiting the mTOR/NF-κB signal pathway.
    Wang Y; Dong F; Wan W; Zhang Z; Wang J; Wang H; Ke X
    Hematology; 2020 Dec; 25(1):424-432. PubMed ID: 33191863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway.
    Yang L; Chen J; Han X; Zhang E; Huang X; Guo X; Chen Q; Wu W; Zheng G; He D; Zhao Y; Yang Y; He J; Cai Z
    Protein Cell; 2018 Sep; 9(9):770-784. PubMed ID: 29441489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.
    Zhao Y; Zhang K; Li G; Zhang X; Shi D
    PLoS One; 2015; 10(5):e0127334. PubMed ID: 25973846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
    Du J; Liu S; He J; Liu X; Qu Y; Yan W; Fan J; Li R; Xi H; Fu W; Zhang C; Yang J; Hou J
    Oncotarget; 2015 Jun; 6(17):14993-5007. PubMed ID: 25915427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cluster Gauss-Newton and CellNOpt Parameter Estimation in a Small Protein Signaling Network of Vorinostat and Bortezomib Pharmacodynamics.
    Niu J; Nguyen VA; Ghasemi M; Chen T; Mager DE
    AAPS J; 2021 Oct; 23(6):110. PubMed ID: 34622346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
    Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAFF is involved in macrophage-induced bortezomib resistance in myeloma.
    Chen J; He D; Chen Q; Guo X; Yang L; Lin X; Li Y; Wu W; Yang Y; He J; Zhang E; Yi Q; Cai Z
    Cell Death Dis; 2017 Nov; 8(11):e3161. PubMed ID: 29095438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling.
    Xu B; Li J; Xu D; Ran Q
    Ir J Med Sci; 2023 Apr; 192(2):561-567. PubMed ID: 35508865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway.
    Xiang RF; Wang Y; Zhang N; Xu WB; Cao Y; Tong J; Li JM; Wu YL; Yan H
    Cell Death Dis; 2017 May; 8(5):e2776. PubMed ID: 28492559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.